Q&A with Sanofi: Nexviazyme Safely Aids Muscle Strength in LOPD

Q&A with Sanofi: Nexviazyme Safely Aids Muscle Strength in LOPD

303891

Q&A with Sanofi: Nexviazyme Safely Aids Muscle Strength in LOPD

Newly approved, Nexviazyme (avalglucosidase alfa) is a next-generation, alternative enzyme replacement therapy for late-onset Pompe disease patients starting at age 1. In clinical trials that supported the Aug. 6 approval by the U.S. Food and Drug Administration (FDA), meaningful improvements in respiratory muscle strength and mobility were evident in patients given Nexviazyme relative to those on Lumizyme  (alglucosidase alfa), the disease’s only other approved enzyme replacement therapy (ERT). Sanofi developed and markets both treatments. Recommended Reading August 9,…

You must be logged in to read/download the full post.